Low sensitivity and frequent cross-reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis

the Cysticercosis Working Group in Peru

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Objective: To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa® and Ridascreen®, for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentil-lectin purified glycoprotein antigens). Methods: Archive serum samples from patients with viable NCC (n = 45) or resolved, calcified NCC (n = 45), as well as sera from patients with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45), were evaluated for cysticercosis antibody detection using two ELISA kits, Novalisa® and Ridascreen®. All NCC samples had previously tested positive, and all samples from heterologous infections were negative on LLGP-EITB for cysticercosis. Positive rates were calculated by kit and sample group and compared between the two kits. Results: Compared to LLGP-EITB, the sensitivity of both ELISA assays to detect specific antibodies in patients with viable NCC was low (44.4% and 22.2%), and for calcified NCC, it was only 6.7% and 4.5%. Sera from patients with cystic hydatid disease were highly cross-reactive in both ELISA assays (38/45, 84.4%; and 25/45, 55.6%). Sera from patients with hymenolepiasis cross-reacted in five cases in one of the assays (11.1%) and in only one sample with the second assay (2.2%). Conclusions: The performance of Novalisa® and Ridascreen® was poor. Antibody ELISA detection cannot be recommended for the diagnosis of neurocysticercosis.

Original languageEnglish
Pages (from-to)101-105
Number of pages5
JournalTropical Medicine and International Health
Issue number1
StatePublished - Jan 2018

Bibliographical note

Funding Information:
We are very grateful to Y. Santos for her hard work on sample processing. Other members of the CWGP include Victor C.W.Tsang, PhD (Coordination Board); Silvia Rodriguez, MSc; Manuel Martinez, MD; Manuel Alvar-ado, MD; Miguel Porras, MD; Victor Vargas, MD; Alfredo Ccjuno, MD (Instituto Nacional de Ciencias Neurológicas, Lima, Perú); Manuela Verastegui, PhD; Mirko Zimic, PhD; Holger Mayta, PhD; Cristina Guerra, PhD; Yesenia Castillo, MSc; Yagahira Castro, MSc (Universidad Peruana Cayetano Heredia, Lima, Perú); Maria T. Lopez, DVM, PhD; Cesar M. Gavidia, DVM, PhD; Luis Gomez, DVM (School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos, Lima, Perú); Luz M. Moyano, MD; Ricardo Gamboa, MSc; Claudio Muro, Percy Vilchez, MSc (Cysticercosis Elimination Program, Tumbes, Perú); Theodore E. Nash, MD; Siddhartha Mahanty, MD, PhD (NIAID, NIH, Bethesda, MD); John Noh, BS; Sukwan Handali, MD (CDC, Atlanta, GA); Jon Friedland (Imperial College, London, UK). This study was partially supported by grant D43TW001140 from the Fogarty International Center of the US National Institutes of Health (YC, JAB).

Publisher Copyright:
© 2017 John Wiley & Sons Ltd


  • Peru
  • Taenia solium
  • antibody
  • cysticercosis
  • neurocysticercosis


Dive into the research topics of 'Low sensitivity and frequent cross-reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis'. Together they form a unique fingerprint.

Cite this